Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
Sponsor: Centre Oscar Lambret
Summary
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients. Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy. The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2005-05
Completion Date
2010-12-03
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
FDG-PET
370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
Locations (1)
Centre Oscar Lambret
Lille, France